# SPRYD4

## Overview
SPRYD4 is a gene that encodes the protein SPRY domain containing 4, which is characterized by the presence of a SPRY domain. This domain is known for facilitating protein-protein interactions, which are essential for the protein's function in various cellular processes, including tumor suppression. The SPRY domain containing 4 protein is implicated in the regulation of cell growth, apoptosis, and immune responses, particularly in the context of cancer biology. It has been identified as a tumor suppressor in cholangiocarcinoma (CCA) and hepatocellular carcinoma (HCC), where its expression levels are inversely correlated with tumor progression and patient prognosis. The protein's interactions with other cellular components suggest its involvement in complex signaling pathways that influence immune cell behavior within the tumor microenvironment (Ma2023Identification; Liu2020Construction).

## Clinical Significance
SPRYD4 has been identified as a tumor suppressor gene with significant implications in various cancers. In cholangiocarcinoma (CCA), low expression of SPRYD4 is associated with poor clinicopathological characteristics, including poor tumor differentiation, positive lymph node metastasis, and advanced TNM stage. Patients with reduced SPRYD4 expression exhibit poorer overall survival and disease-free survival, suggesting its potential as a prognostic marker and therapeutic target in CCA (Ma2023Identification). Overexpression of SPRYD4 in CCA cells has been shown to inhibit cell proliferation and migration, induce S/G2 phase arrest, and promote apoptosis, highlighting its role in tumor suppression (Ma2023Identification).

In hepatocellular carcinoma (HCC), SPRYD4 is similarly downregulated, and its exogenous expression inhibits cell proliferation by inducing apoptosis, reinforcing its function as a tumor suppressor (Liu2020Construction). The gene is also implicated in kidney function, with studies suggesting its involvement in chronic kidney disease (CKD) progression, although specific diseases directly linked to SPRYD4 mutations or expression alterations are not well-documented (Schlosser2023Transcriptome). These findings indicate that SPRYD4 plays a crucial role in cancer progression and may influence immune response modulation.

## Interactions
SPRYD4, a gene encoding a protein with a SPRY domain, is involved in various protein-protein interactions that play significant roles in cellular processes. The SPRY domain is known for mediating interactions, which are crucial for the protein's function as a tumor suppressor in cholangiocarcinoma (CCA). SPRYD4 interacts with a network of genes and proteins, including AMBRA1, CCL5, GPI, and ATP5ME, as identified through tools like GeneMANIA and STRING (Ma2023Identification). These interactions suggest that SPRYD4 is involved in biological processes such as cell growth, apoptosis, immune response, and drug metabolism.

The protein-protein interaction (PPI) network constructed in the study highlights correlations with proteins such as SPPL2B, LYZL6, and YEATS4, indicating SPRYD4's involvement in complex cellular pathways (Ma2023Identification). Functional enrichment analyses further reveal that SPRYD4 is associated with immune infiltration in CCA, negatively correlating with tumor-infiltrating lymphocytes (TILs) and immune checkpoint markers like PD-1, PD-L1, and CTLA4 (Ma2023Identification). These interactions suggest that SPRYD4 may regulate tumor-specific immune responses, potentially influencing the behavior of immune cells within the tumor microenvironment.


## References


[1. (Ma2023Identification) Zuyi Ma, Tiange Xie, Jia Sun, Jianchun Yu, Shanzhou Huang, Qi Zhou, and Binglu Li. Identification of spryd4 as a tumour suppressor predicts prognosis and correlates with immune infiltration in cholangiocarcinoma. BMC Cancer, May 2023. URL: http://dx.doi.org/10.1186/s12885-023-10810-9, doi:10.1186/s12885-023-10810-9. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12885-023-10810-9)

[2. (Schlosser2023Transcriptome) Pascal Schlosser, Jingning Zhang, Hongbo Liu, Aditya L. Surapaneni, Eugene P. Rhee, Dan E. Arking, Bing Yu, Eric Boerwinkle, Paul A. Welling, Nilanjan Chatterjee, Katalin Susztak, Josef Coresh, and Morgan E. Grams. Transcriptome- and proteome-wide association studies nominate determinants of kidney function and damage. Genome Biology, June 2023. URL: http://dx.doi.org/10.1186/s13059-023-02993-y, doi:10.1186/s13059-023-02993-y. This article has 9 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1186/s13059-023-02993-y)

[3. (Liu2020Construction) Ziyu Liu, Yan Lin, Xing Gao, Rongyun Mai, Xuemin Piao, Jiazhou Ye, and Rong Liang. Construction of a comprehensive multiomics map of hepatocellular carcinoma and screening of possible driver genes. Frontiers in Genetics, June 2020. URL: http://dx.doi.org/10.3389/fgene.2020.00634, doi:10.3389/fgene.2020.00634. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2020.00634)